GlassScriptPhysician profile
Ammar Tarabichi
NPI 1750941639
$1,031.46
in general payments reported to CMS, 2019-2025
21 companies · $64.59 in 2025
The $64.59 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $18.88 · 2023: $290 · 2024: $658 · 2025: $64.59.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,013.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,012.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $255.31 | 2023-2024 | Nayzilam, Rystiggo |
| Otsuka America Pharmaceutical, INC. | $145.92 | 2023-2025 | Rexulti, Abilify Asimtufii, Nuedexta |
| Teva Pharmaceuticals USA, INC. | $111.61 | 2023-2024 | Austedo Xr, Ajovy |
| Amgen INC. | $93.47 | 2024 | Uplizna |
| Kyowa Kirin, INC. | $52.11 | 2023-2024 | Nourianz |
| Eisai INC. | $49.19 | 2024-2025 | |
| Lilly USA, LLC | $46.18 | 2023-2025 | Emgality, Reyvow, Kisunla |
| Lundbeck LLC | $31.78 | 2023-2024 | Vyepti, Rexulti |
| Abbvie INC. | $27.78 | 2024 | |
| Novo Nordisk INC | $22.61 | 2023 | Wegovy |
| Alexion Pharmaceuticals, INC. | $22.33 | 2024 | Ultomiris |
| Averitas Pharma INC. | $22.32 | 2024 | Qutenza |
| Collegium Pharmaceutical, INC. | $21.75 | 2024 | Belbuca |
| Amneal Pharmaceuticals LLC | $21.20 | 2024 | Avastin |
| Janssen Pharmaceuticals, INC | $20.25 | 2024 | Spravato |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $18.88 | 2020 | |
| Orexo US, INC. | $18.48 | 2024 | Zubsolv |
| Jazz Pharmaceuticals INC. | $17.74 | 2024 | |
| Ibsa Pharma INC. | $16.70 | 2024 | Licart, Tirosint |
| Alnylam Pharmaceuticals INC. | $15.85 | 2024 | Onpattro |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$12,998.84 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ammar Tarabichi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.